In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer: Will the Pillars Crumble?

Executive Summary

Bayer's voluntary withdrawal of cholesterol drug Baycol increased the pressure on the German chemicals conglomerate to sell its pharmaceuticals business. Bayer's decision to hold on to it--albeit less tightly--reflects both strategic and cultural concerns.
Advertisement

Related Content

Generic Plavix: As Bristol Swoons, Broad Implications
The Anti-Global, Specialist Strategy: Why Bayer's Choice Might Be Right for Other Pharmas
The Anti-Global, Specialist Strategy: Why Bayer's Choice Might Be Right for Other Pharmas
Organon Kicks Off Partnering Strategy with Pfizer Deal
GW/Bayer: Sharing Value
Bayer Leans on Vardenafil

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001740

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel